Search Results - "Marano, Colleen"

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis by Sands, Bruce E, Sandborn, William J, Panaccione, Remo, O’Brien, Christopher D, Zhang, Hongyan, Johanns, Jewel, Adedokun, Omoniyi J, Li, Katherine, Peyrin-Biroulet, Laurent, Van Assche, Gert, Danese, Silvio, Targan, Stephan, Abreu, Maria T, Hisamatsu, Tadakazu, Szapary, Philippe, Marano, Colleen

“…Patients with moderate-to-severe ulcerative colitis were randomly assigned to receive placebo or induction doses of ustekinumab. Patients who had a response to…”
Get full text

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis by Colombel, Jean Frédéric, Rutgeerts, Paul, Reinisch, Walter, Esser, Dirk, Wang, Yanxin, Lang, Yinghua, Marano, Colleen W, Strauss, Richard, Oddens, Björn J, Feagan, Brian G, Hanauer, Stephen B, Lichtenstein, Gary R, Present, Daniel, Sands, Bruce E, Sandborn, William J

“…Background & Aims In the Active Ulcerative Colitis Trial (ACT)-1 and ACT-2, patients with ulcerative colitis treated with infliximab were more likely than…”
Get full text

Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis by Adedokun, Omoniyi J, Sandborn, William J, Feagan, Brian G, Rutgeerts, Paul, Xu, Zhenhua, Marano, Colleen W, Johanns, Jewel, Zhou, Honghui, Davis, Hugh M, Cornillie, Freddy, Reinisch, Walter

“…Background & Aims We analyzed data collected during the Active Ulcerative Colitis Trials (ACT-1 and ACT-2) to assess relationships between serum concentrations…”
Get full text

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study by Landells, Ian, MD, FRCPC, Marano, Colleen, PhD, Hsu, Ming-Chun, PhD, Li, Shu, PhD, Zhu, Yaowei, PhD, Eichenfield, Lawrence F., MD, Hoeger, Peter H., MD, Menter, Alan, MD, Paller, Amy S., MS, MD, Taieb, Alain, MD, Philipp, Sandra, MD, Szapary, Philippe, MD, MSCE, Randazzo, Bruce, MD, PhD

“…Background Safe and effective therapies are needed for pediatric patients with psoriasis. Objective The purpose of this study was to evaluate ustekinumab in…”
Get full text

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy by Panaccione, Remo, Danese, Silvio, Sandborn, William J., O'Brien, Christopher D., Zhou, Yiying, Zhang, Hongyan, Adedokun, Omoniyi J., Tikhonov, Ilia, Targan, Stephan, Abreu, Maria T., Hisamatsu, Tadakazu, Scherl, Ellen J., Leong, Rupert W., Rowbotham, David S., Arasaradnam, Ramesh P., Sands, Bruce E., Marano, Colleen

“…Summary Background The ongoing UNIFI long‐term extension evaluates subcutaneous ustekinumab for moderate‐to‐severe ulcerative colitis (UC) from weeks 44…”
Get full text

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension by Abreu, Maria T, Rowbotham, David S, Danese, Silvio, Sandborn, William J, Miao, Ye, Zhang, Hongyan, Tikhonov, Ilia, Panaccione, Remo, Hisamatsu, Tadakazu, Scherl, Ellen J, Leong, Rupert W, Arasaradnam, Ramesh P, Afif, Waqqas, Peyrin-Biroulet, Laurent, Sands, Bruce E, Marano, Colleen

“…Abstract Background and Aims The UNIFI long-term extension [LTE] study reports the efficacy and safety of subcutaneous 90 mg ustekinumab through 3 years of…”
Get full text

Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies by Adedokun, Omoniyi J, Xu, Zhenhua, Marano, Colleen W, Strauss, Richard, Zhang, Hongyan, Johanns, Jewel, Zhou, Honghui, Davis, Hugh M, Reinisch, Walter, Feagan, Brian G, Rutgeerts, Paul, Sandborn, William J

“…To assess golimumab pharmacokinetics [PK] and exposure-response [ER] in adults with moderate-to-severe ulcerative colitis [UC] from the Program of Ulcerative…”
Get full text

Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial by Gottlieb, Alice B., Evans, Robert, Li, Shu, Dooley, Lisa T., Guzzo, Cynthia A., Baker, Daniel, Bala, Mohan, Marano, Colleen W., Menter, Alan

“…Tumor necrosis factor–α is a key mediator in the pathogenesis of psoriasis. Infliximab is a monoclonal antibody that specifically binds to tumor necrosis…”
Get full text

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI) by Hisamatsu, Tadakazu, Kim, Hyo Jong, Motoya, Satoshi, Suzuki, Yasuo, Ohnishi, Yoshifumi, Fujii, Noriyuki, Matsushima, Nobuko, Zheng, Richuan, Marano, Colleen W.

“…Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative…”
Get full text

Positive treatment effects of ustekinumab in psoriasis: Analysis of lesional and systemic parameters by REDDY, Manjula, TORRES, Gisela, McCORMICK, Thomas, MARANO, Colleen, COOPER, Kevin, YEILDING, Newman, WANG, Yuhua, PENDLEY, Charles, PRABHAKAR, Uma, WONG, Jackson, DAVIS, Cuc, XU, Stephen, BRODMERKEL, Carrie

“…Ustekinumab, a human anti‐interleukin (IL)‐12/IL‐23p40 monoclonal antibody has demonstrated significant efficacy in patients with moderate‐to‐severe psoriasis…”
Get full text

Improvement in Biomarkers of Bone Formation During Infliximab Therapy in Pediatric Crohn's Disease: Results of the REACH Study by Thayu, Meena, Leonard, Mary B, Hyams, Jeffrey S, Crandall, Wallace V, Kugathasan, Subra, Otley, Anthony R, Olson, Allan, Johanns, Jewel, Marano, Colleen W, Heuschkel, Robert B, Veereman–Wauters, Gigi, Griffiths, Anne M, Baldassano, Robert N

“…Background & Aims Crohn's disease (CD) is associated with altered bone metabolism. This study examined changes in bone formation and resorption after…”
Get full text

Sa1266 Interferon-γ Release Assay Versus Tuberculin Skin Test in Patients With Moderate-to-Severely Active Ulcerative Colitis: Results From the PURSUIT UC Program by Marano, Colleen W, Hsia, Elizabeth C, Xu, Stephen, Sandborn, William, Rutgeerts, Paul J

Get full text

Su1763 Distinctive Gene Expression Profiles in the Whole Blood of Patients With Moderate to Severe Ulcerative Colitis and Crohn's Disease by Telesco, Shannon, Li, Katherine, Marano, Colleen W, Gasink, Christopher, Ma, Keying, Strauss, Richard, Brodmerkel, Carrie

Get full text

Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease by Geboes, Karel, Rutgeerts, Paul, Opdenakker, Ghislain, Olson, Allan, Patel, Kamlesh, Wagner, Carrie L., Marano, Colleen W.

“…ABSTRACT Objectives: The long-term effect of infliximab on endoscopic and histologic disease activity and expression of inflammatory markers was assessed in…”
Get full text

Mo1214 Long-Term Safety and Efficacy of Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the PURSUIT-SC Maintenance Study Extension by Gibson, Peter R, Reinisch, Walter, Sandborn, William, Feagan, Brian G, Marano, Colleen W, Strauss, Richard, Johanns, Jewel, Zhang, Hongyan, Padgett, Lakshmi, Colombel, Jean-Frederic, Collins, Judith, Rutgeerts, Paul J

Get full text

Su1745 Characterization of Molecular Response to Golimumab in Ulcerative Colitis by mRNA Expression Profiling: Results From Pursuit-SC Induction Study by Li, Katherine, Telesco, Shannon, Rutgeerts, Paul J, Sandborn, William, Marano, Colleen W, Ma, Keying, Johanns, Jewel, Zhang, Hongyan, Strauss, Richard, Reinisch, Walter, Colombel, Jean-Frederic, Brodmerkel, Carrie

Get full text

Mo1215 Serum Golimumab Exposure and the Incidence of Selected Safety Events in Patients With Ulcerative Colitis Following Treatment With Golimumab: An Exploratory Analysis of the PURSUIT Study Data by Adedokun, Omoniyi J, Xu, Zhenhua, Marano, Colleen W, Strauss, Richard, Zhang, Hongyan, Johanns, Jewel, Zhou, Honghui, Davis, Hugh M, Liao, Sam, Colombel, Jean-Frederic, Reinisch, Walter, Feagan, Brian G, Rutgeerts, Paul J, Gibson, Peter R, Sandborn, William

Get full text

566 Infliximab Concentration and Clinical Outcome in Patients With Ulcerative Colitis by Reinisch, Walter, Feagan, Brian G, Rutgeerts, Paul J, Adedokun, Omoniyi J, Cornillie, Freddy J, Diamond, Robert, Marano, Colleen W, Sandborn, William J

Get full text

Clinical Response Is a Meaningful Endpoint in Ulcerative Colitis Clinical Studies: P-30 by Sandborn, William, Feagan, Brian, Marano, Colleen, Strauss, Richard, Johanns, Jewel, Zhang, Hongyan, Guzzo, Cynthia, Colombel, Jean-Frédéric, Reinisch, Walter, Gibson, Peter, Collins, Judith, Jarnerot, Gunnar, Rutgeerts, Paul

Get full text

W1228 Genes Associated With Reduced Epithelial Permeability and Epithelial-Mesenchymal Transition: Changes in Expression Following Infliximab Therapy in Ulcerative Colitis by Toedter, Gary, Ma, Keying, Li, Katherine, Marano, Colleen W, Macoritto, Michael, Park, Jennifer, Kenney, Renee Deehan, Matthews, Andrea, Wu, Gary D, Lewis, James D, Rutgeerts, Paul J, Baribaud, Frederic

Get full text